No Picture
News

Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today

CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year 2021 first quarter, ended June 30, 2020.
Business hig… […]

No Picture
News

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

– Advancing Precommercial Activities in Preparation for Phexxi(TM) Commercial Launch in September 2020 — Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation — Management to Host Conference Call Tu… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]

No Picture
News

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

Conference Call and Webcast Scheduled for Monday, August 3

SAN DIEGO, July 13, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Mon… […]

No Picture
News

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

– Complete Response Letter Requests Additional Non-Clinical Information — No Clinical Safety or Efficacy Issues and No Chemistry, Manufacturing and Controls (CMC) Issues Identified — Conference Call and Webcast Today at 9:00 a.m. ET –

SAN DIEGO, Ju… […]

No Picture
News

Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

Live Webcast will be on June 22, 2020

SAN DIEGO, June 15, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22… […]

No Picture
News

Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

Live Webcast will be on June 11, 2020

SAN DIEGO, June 4, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday, June 11, 2020. K… […]

No Picture
News

Halozyme Reports First Quarter 2020 Results

– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]

No Picture
News

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020

Live Audio Webcast will be on May 12, 2020

SAN DIEGO, May 5, 2020 /PRNewswire/ –?Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevi… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020

— Conference Call Scheduled for 11:00 a.m. ET —- Key U.S. Regulatory Milestones Remain on Track, Including May 25, 2020 PDUFA Date —

SAN DIEGO, April 28, 2020 /PRNewswire/ –?Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceut… […]